Previous 10 | Next 10 |
Gainers: Creative Realities (NASDAQ:CREX) +128%. Casper Sleep (NYSE:CSPR) +86%. Siyata Mobile (NASDAQ:SYTA) +33%. Patriot National Bancorp (NASDAQ:PNBK) +35%. SilverSun Technologies (NASDAQ:SSNT) +26%. The Vita CoCo (NASDAQ:COCO) +24%. Trio-Tech (NYSE:TRT) +24%. Gores Guggenheim (NASDAQ:GGPI)...
—Results demonstrate sustained benefit across clinical, functional and biomarker endpoints in all four patients with long-term follow up— — NYHA class improvement (from II to I) in all three patients (two low-dose, one high-dose) with closely monitored...
—Company to provide comprehensive update on the ongoing Phase 1 clinical trial of RP-A501, including data to be presented at the American Heart Association (AHA) Scientific Sessions 2021— Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 202...
—Updated clinical data from the ongoing Phase 1 trial of RP-A501 to be presented— Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today...
— Updated clinical data to be presented from ongoing Phase 2 registrational trials in LAD-I and FA and Phase 1 trial in PKD— Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of ge...
Rocket Pharmaceuticals (NASDAQ:RCKT): Q3 GAAP EPS of -$0.79 misses by $0.18. Cash, cash equivalents and investments as of September 30, 2021, were $421.5 million. Press Release Shares -1.79% PM For further details see: Rocket Pharmaceuticals EPS misses by $0.18
— Treatment initiated in pediatric patient cohort in Danon Disease trial of RP-A501— — Treatment completed in nine of nine patients in LAD-1 Phase 1/2 trial; favorable safety profile and initial clinical benefit reported in all seven patients with at l...
—RP-L201 is well tolerated and leads to durable CD18 expression and consistent peripheral vector copy numbers in seven of the initial seven patients with follow-up ranging from 3 to 18 months — — Positive data updates show initial clinical benefit with no ...
—Incremental updates in LAD-I and PKD and previously disclosed data in FA to be presented— —Clinical updates across all programs anticipated later in Q4— Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing a...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...